Featured 13F manager
Farallon Capital Management, L.l.c.
San Francisco, CA 87 processed 13Fs on this site · 2021 Q3–2026 Q2
- $21.7B
- 77 Positions
- 2026 Q2
- +23.6% QoQ
- Top 5 29.9%
Portfolio
top 5 29.9% · top 10 44.0%
- RVMD - Revolution Medicines 11.7%
- EA - Electronic Arts 7.5%
- BBIO - Bridgebio Pharma 3.7%
- PTGX - Protagonist Therapeutics 3.6%
- EXEL - Exelixis 3.4%
- LQDA - Liquidia 3.1%
- AMZN - Amazon 2.9%
- LNTH - Lantheus 2.9%
- NTRA - Natera 2.8%
- UNH - Unitedhealth Group 2.4%
- TMO - Thermo Fisher Scientific 2.4%
- ROIV - Roivant Sciences 2.3%
- Other 51.3%
AUM over time
Book
| SPY - Spdr S&P 500 ETF Tr | 14.66% | New | 5,500,000 | $617.85 | $3.4B | +5,500,000 | +$3.4B |
| MSFT - Microsoft | 3.75% | Reduce −23.5% | 1,747,835 | $497.41 | $869M | −538,000 | +$11M |
| NTRA - Natera | 3.51% | Add +6.0% | 4,821,809 | $168.94 | $815M | +274,000 | +$171M |
| HESS | 3.47% | New | 5,805,000 | $138.54 | $804M | +5,805,000 | +$804M |
| AON - AON PLC · CL A | 3.06% | Add +45.9% | 1,986,417 | $356.76 | $709M | +624,673 | +$330M |
| EXEL - Exelixis | 3.05% | Reduce −28.8% | 16,035,500 | $44.08 | $707M | −6,498,000 | −$125M |
| AMZN - Amazon | 2.87% | New | 3,034,600 | $219.39 | $666M | +3,034,600 | +$666M |
| IQV - IQVIA | 2.62% | Add +12.9% | 3,851,351 | $157.59 | $607M | +439,500 | +$5M |
| DIS - Disney Walt | 2.61% | Reduce −11.3% | 4,874,268 | $124.01 | $604M | −621,955 | +$62M |
| CRM - Salesforce | 2.48% | Add +7.2% | 2,109,110 | $272.69 | $575M | +142,000 | +$47M |
| TMO - Thermo Fisher Scientific | 2.42% | Add +33.5% | 1,383,241 | $405.46 | $561M | +347,385 | +$45M |
| LNTH - Lantheus | 2.37% | Add +11.6% | 6,722,227 | $81.86 | $550M | +699,000 | −$38M |
| ARMK - Aramark | 2.33% | Reduce −20.6% | 12,899,701 | $41.87 | $540M | −3,342,295 | −$21M |
| ADSK - Autodesk | 2.33% | Reduce −12.7% | 1,744,652 | $309.57 | $540M | −252,748 | +$17M |
| RVMD - Revolution Medicines | 2.27% | Add +5.8% | 14,325,692 | $36.79 | $527M | +791,000 | +$48M |
| UNH - Unitedhealth Group | 2.18% | Add +8.0% | 1,617,300 | $311.97 | $505M | +119,400 | −$280M |
| TRU - Transunion | 2.05% | Reduce −0.2% | 5,404,575 | $88.00 | $476M | −8,631 | +$26M |
| GBTC - Ishares Bitcoin Trust ETF | 1.85% | Add +21.2% | 7,020,050 | $61.21 | $430M | +1,226,250 | +$158M |
| BSX - Boston Scientific | 1.84% | Add +5.8% | 3,981,057 | $107.41 | $428M | +218,300 | +$48M |
| INTU - Intuit | 1.82% | Reduce −36.1% | 536,658 | $787.63 | $423M | −303,600 | −$93M |
| HIMS - Hims & Hers Health · CL A | 1.77% | Add +3.3% | 8,213,581 | $49.85 | $409M | +259,876 | +$174M |
| NDAQ - Nasdaq | 1.58% | Reduce −8.4% | 4,083,743 | $89.42 | $365M | −376,545 | +$27M |
| SCHW - Schwab Charles | 1.56% | Add +3.3% | 3,959,057 | $91.24 | $361M | +126,200 | +$61M |
| ANSS - Ansys | 1.51% | New | 997,128 | $351.22 | $350M | +997,128 | +$350M |
| PTGX - Protagonist Therapeutics | 1.47% | Add +1.1% | 6,172,006 | $55.27 | $341M | +65,000 | +$46M |
| BBIO - Bridgebio Pharma | 1.47% | Add +37.8% | 7,900,000 | $43.18 | $341M | +2,169,000 | +$143M |
| NYT - New York Times · CL A | 1.35% | Reduce −37.2% | 5,609,546 | $55.98 | $314M | −3,322,567 | −$129M |
| GOOG - Alphabet · CL C | 1.35% | Add +5.8% | 1,761,840 | $177.39 | $313M | +95,800 | +$52M |
| ADI - Analog Devices | 1.31% | Reduce −4.1% | 1,272,200 | $238.02 | $303M | −54,800 | +$35M |
| CBRE - CBRE Group · CL A | 1.28% | Reduce −15.3% | 2,113,138 | $140.12 | $296M | −382,562 | −$30M |
| WAB - Wabtec | 1.18% | Reduce −18.6% | 1,308,198 | $209.35 | $274M | −299,900 | −$18M |
| MCK - Mckesson | 0.99% | Reduce −43.1% | 314,600 | $732.78 | $231M | −237,900 | −$141M |
| WWD - Woodward | 0.97% | Reduce −35.6% | 914,673 | $245.09 | $224M | −505,027 | −$35M |
| AGIO - Agios Pharmaceuticals | 0.83% | Add +1.2% | 5,767,466 | $33.26 | $192M | +67,000 | +$25M |
| Verona Pharma | 0.74% | Add +66.8% | 1,810,000 | $94.58 | $171M | +725,011 | +$102M |
| AZEK · CL A | 0.74% | New | 3,141,400 | $54.35 | $171M | +3,141,400 | +$171M |
| BEAM - Beam Therapeutics | 0.73% | Add +0.9% | 10,013,111 | $17.01 | $170M | +85,000 | −$24M |
| CRNX — | 0.58% | Add +0.9% | 4,646,098 | $28.76 | $134M | +41,000 | −$21M |
| V - VISA · CL A | 0.47% | Reduce −34.9% | 308,810 | $355.05 | $110M | −165,400 | −$57M |
| Championx | 0.45% | New | 4,245,000 | $24.84 | $105M | +4,245,000 | +$105M |
| GEHC - GE HealthCare | 0.42% | Add +146.2% | 1,322,000 | $74.07 | $98M | +785,000 | +$55M |
| THC - Tenet Healthcare | 0.40% | New | 529,000 | $176.00 | $93M | +529,000 | +$93M |
| EHC - Encompass Health | 0.37% | Add +14.4% | 708,000 | $122.63 | $87M | +89,000 | +$24M |
| MA - Mastercard · CL A | 0.37% | Reduce −24.5% | 152,071 | $561.94 | $85M | −49,300 | −$25M |
| CAH - Cardinal Health | 0.33% | Add +66.3% | 454,000 | $168.00 | $76M | +181,000 | +$39M |
| EDU — | 0.27% | Reduce −11.5% | 1,155,150 | $53.95 | $62M | −150,000 | −$79K |
| BBNX - Beta Bionics | 0.26% | Add +26.2% | 4,203,920 | $14.56 | $61M | +871,700 | +$20M |
| CNTA - Centessa Pharmaceuticals | 0.26% | Add +4.5% | 4,529,318 | $13.14 | $60M | +195,000 | −$3M |
| LQDA - Liquidia | 0.23% | Add +6.2% | 4,238,762 | $12.46 | $53M | +247,806 | −$6M |
| FLUT - Flutter Entmt | 0.22% | Reduce −24.9% | 181,229 | $285.76 | $52M | −60,238 | −$2M |
| TNGX - Tango Therapeutics | 0.20% | Add +98.6% | 9,157,000 | $5.12 | $47M | +4,546,070 | +$41M |
| SGRY - Surgery Partners | 0.18% | New | 1,926,000 | $22.23 | $43M | +1,926,000 | +$43M |
| Verve Therapeutics | 0.18% | Add +296.1% | 3,612,000 | $11.23 | $41M | +2,700,000 | +$36M |
| JOYY — | 0.17% | Add +1.0% | 787,906 | $50.91 | $40M | +7,906 | +$7M |
| HQY - Healthequity | 0.14% | Reduce −24.2% | 319,800 | $104.76 | $34M | −102,000 | −$4M |
| RARE — | 0.14% | New | 898,000 | $36.36 | $33M | +898,000 | +$33M |
| OSCR - Oscar Health · CL A | 0.14% | Add +13318.2% | 1,476,000 | $21.44 | $32M | +1,465,000 | +$32M |
| WGS - Genedx · CL A | 0.13% | Add +7.8% | 326,677 | $92.31 | $30M | +23,677 | +$3M |
| GRAL - Grail | 0.11% | New | 502,000 | $51.42 | $26M | +502,000 | +$26M |
| WAY - Waystar | 0.11% | Reduce −69.7% | 613,000 | $40.87 | $25M | −1,407,000 | −$50M |
| SDGR - Schrodinger | 0.10% | New | 1,106,000 | $20.12 | $22M | +1,106,000 | +$22M |
| VNET - VNET Group | 0.09% | Add +22.8% | 2,994,120 | $6.90 | $21M | +555,000 | +$659K |
| ALKS - Alkermes | 0.09% | Reduce −50.2% | 691,663 | $28.61 | $20M | −698,137 | −$26M |
| ABT - Abbott Labs | 0.08% | Reduce −59.2% | 136,000 | $136.01 | $18M | −197,000 | −$26M |
| YMM - Full Truck Alliance | 0.08% | Reduce −78.9% | 1,550,598 | $11.81 | $18M | −5,806,609 | −$76M |
| Mr Cooper Group | 0.08% | New | 122,500 | $149.21 | $18M | +122,500 | +$18M |
| PARA - Paramount Global · CLASS B | 0.07% | New | 1,346,151 | $12.90 | $17M | +1,346,151 | +$17M |
| TECX - Tectonic Therapeutic | 0.07% | Hold | 853,050 | $19.87 | $17M | — | — |
| ENTA - Enanta Pharmaceuticals | 0.07% | Hold | 2,122,262 | $7.56 | $16M | — | — |
| Savara | 0.07% | Hold | 6,835,000 | $2.28 | $16M | — | — |
| MARA | 0.06% | Hold | 835,000 | $15.68 | $13M | — | — |
| Latam Airlines Group SA | 0.06% | Reduce −43.4% | 318,092 | $40.64 | $13M | −243,918 | −$5M |
| GMED - Globus Med · CL A | 0.05% | Add +153.0% | 210,000 | $59.02 | $12M | +127,000 | +$6M |
| NUVL - Nuvalent | 0.05% | Hold | 150,000 | $76.30 | $11M | — | — |
| TYRA - Tyra Biosciences | 0.05% | Hold | 1,143,818 | $9.57 | $11M | — | — |
| CDTX - Cidara Therapeutics | 0.04% | New | 200,000 | $48.71 | $10M | +200,000 | +$10M |
| Helix Acquisition Ii · CL A | 0.03% | Hold | 600,000 | $10.65 | $6M | — | — |
| VYGR - Voyager Therapeutics | 0.01% | Reduce −72.2% | 715,000 | $3.11 | $2M | −1,855,700 | −$6M |
| PRME - Prime Medicine | 0.01% | Hold | 750,000 | $2.47 | $2M | — | — |
| ALVO - Alvotech | 0.01% | Hold | 199,675 | $9.12 | $2M | — | — |
| SMC - Summit Midstream | 0.01% | Hold | 58,214 | $24.53 | $1M | — | — |
| Janux Therapeutics | 0.00% | Hold | 48,000 | $23.10 | $1M | — | — |
| MDGL - Madrigal Pharmaceuticals | 0.00% | Hold | 3,319 | $302.64 | $1M | — | — |
| BTSG - Brightspring Health Svcs | 0.00% | Hold | 22,000 | $23.59 | $519K | — | — |
| SLNOEUR - Soleno Therapeutics | 0.00% | Hold | 5,000 | $83.78 | $419K | — | — |
| AXSM - Axsome Therapeutics | 0.00% | Hold | 4,000 | $104.39 | $418K | — | — |
| ROIV - Roivant Sciences | 0.00% | Hold | 37,000 | $11.27 | $417K | — | — |
| CAPR - Capricor Therapeutics | 0.00% | Reduce −98.2% | 41,000 | $9.93 | $407K | −2,209,400 | −$21M |
| PGNY - Progyny | 0.00% | Hold | 18,000 | $22.00 | $396K | — | — |
| Sage Therapeutics | 0.00% | Hold | 42,800 | $9.12 | $390K | — | — |
| ARQT - Arcutis Biotherapeutics | 0.00% | Hold | 26,000 | $14.02 | $365K | — | — |
| INSM - Insmed | 0.00% | Hold | 3,000 | $100.64 | $302K | — | — |
| COR - Cencora | 0.00% | Hold | 1,000 | $299.85 | $300K | — | — |
| UTHR - United Therapeutics | 0.00% | Hold | 1,000 | $287.35 | $287K | — | — |
| TWST - Twist Bioscience | 0.00% | Hold | 7,650 | $36.79 | $281K | — | — |
| MMSI - Merit Med Sys | 0.00% | Hold | 3,000 | $93.48 | $280K | — | — |
| KRYS - Krystal Biotech | 0.00% | Hold | 2,000 | $137.46 | $275K | — | — |
| LIVN - Livanova | 0.00% | Reduce −83.8% | 6,000 | $45.02 | $270K | −31,000 | −$1M |
| GKOS - Glaukos | 0.00% | Hold | 2,600 | $103.29 | $269K | — | — |
| ONC - Beone Medicines | 0.00% | Hold | 1,100 | $242.07 | $266K | — | — |
| ACLXGBX - Arcellx | 0.00% | Hold | 4,000 | $65.85 | $263K | — | — |
| SBRA - Sabra Health Care Reit | 0.00% | Hold | 14,000 | $18.44 | $258K | — | — |
| GRFS - Grifols S A | 0.00% | Hold | 28,000 | $9.04 | $253K | — | — |
| ARWR - Arrowhead Pharmaceuticals | 0.00% | Hold | 15,800 | $15.80 | $250K | — | — |
| SRRK - Scholar Rock | 0.00% | Hold | 7,000 | $35.42 | $248K | — | — |
| ASND - Ascendis Pharma A/S | 0.00% | Hold | 1,400 | $172.60 | $242K | — | — |
| Springworks Therapeutics | 0.00% | Reduce −95.8% | 5,000 | $46.99 | $235K | −113,000 | −$5M |
| BRKR - Bruker | 0.00% | Hold | 5,000 | $41.20 | $206K | — | — |
| QURE - Uniqure | 0.00% | Hold | 14,000 | $13.94 | $195K | — | — |
| IMVT - Immunovant | 0.00% | Hold | 12,000 | $16.00 | $192K | — | — |
| HR - Healthcare Rlty Tr · CL A | 0.00% | Hold | 12,000 | $15.86 | $190K | — | — |
| PACB — | 0.00% | Hold | 135,000 | $1.24 | $167K | — | — |
| EVH - Evolent Health · CL A | 0.00% | Hold | 14,000 | $11.26 | $158K | — | — |
| COGT - Cogent Biosciences | 0.00% | Hold | 17,000 | $7.18 | $122K | — | — |
| ALT - Altimmune | 0.00% | Hold | 27,600 | $3.87 | $107K | — | — |
| NVAX - Novavax | 0.00% | Hold | 16,000 | $6.30 | $101K | — | — |
| DYN - Dyne Therapeutics | 0.00% | Hold | 10,000 | $9.52 | $95K | — | — |
| SNDX - Syndax Pharmaceuticals | 0.00% | Hold | 10,000 | $9.36 | $94K | — | — |
| AM6 - Amicus Therapeutics | 0.00% | Hold | 16,000 | $5.73 | $92K | — | — |
| ARDX - Ardelyx | 0.00% | Hold | 23,000 | $3.92 | $90K | — | — |
| GERN - Geron | 0.00% | Hold | 43,000 | $1.41 | $61K | — | — |
| ANNA - Aleanna · CL A | 0.00% | Hold | 78,400 | $0.6347 | $50K | — | — |
| IOVA - Iovance Biotherapeutics | 0.00% | Hold | 26,000 | $1.72 | $45K | — | — |
| CCCC - C4 Therapeutics | 0.00% | Hold | 28,000 | $1.43 | $40K | — | — |
| CGC - Canopy Growth | 0.00% | Hold | 30,000 | $1.22 | $37K | — | — |
| Biodesix | 0.00% | Reduce −93.1% | 128,000 | $0.2822 | $36K | −1,731,308 | −$1M |
| IRWD - Ironwood Pharmaceuticals · CL A | 0.00% | Hold | 13,000 | $0.7172 | $9K | — | — |
Showing top 50 of 127 by value
Exits / last held
not current holdings · last reported size, unchanged · gone vs 2025 Q1
| Stock | % of portfolio | Recent activity | Shares | Reported price* | Value | Share change | $ change |
|---|---|---|---|---|---|---|---|
| Intra-Cellular Therapies | 2.25% | Exit | 0 | $131.92 | $403M | −3,055,000 | −$403M |
| Sarepta Therapeutics | 0.83% | Exit | 0 | $63.82 | $149M | −2,341,424 | −$149M |
| BHVN - Biohaven | 0.65% | Exit | 0 | $24.04 | $116M | −4,813,167 | −$116M |
| SGI - Somnigroup International | 0.44% | Exit | 0 | $59.88 | $79M | −1,326,242 | −$79M |
| Zymeworks | 0.03% | Exit | 0 | $11.91 | $5M | −400,000 | −$5M |
| Rxsight | 0.02% | Exit | 0 | $25.25 | $4M | −175,000 | −$4M |
| Marblegate Acquisition · CL A | 0.01% | Exit | 0 | $11.05 | $2M | −150,000 | −$2M |
| SIMO - Silicon Motion Technology | 0.01% | Exit | 0 | $50.55 | $1M | −29,298 | −$1M |
| Cara Therapeutics | — | Exit | 0 | $5.07 | $658K | −129,685 | −$658K |
| Forte Biosciences | — | Exit | 0 | $7.77 | $547K | −70,429 | −$547K |
| Blueprint Medicines | — | Exit | 0 | $88.50 | $354K | −4,000 | −$354K |
| CHE - Chemed | — | Exit | 0 | $615.00 | $246K | −400 | −$246K |
| TMDX - Transmedics Group | — | Exit | 0 | $67.33 | $202K | −3,000 | −$202K |
| ELAN - Elanco Animal Health | — | Exit | 0 | $10.50 | $168K | −16,000 | −$168K |
| Beyond Meat | — | Exit | 0 | $3.05 | $58K | −19,000 | −$58K |
Filings history
20 periods · normalized AUM · open a period for holdings
| Period | Holdings | AUM | QoQ | Form | Filed | Filing ID |
|---|---|---|---|---|---|---|
| 2026 Q2 | 89 | $21.7B | +23.6% | 13F-HR | 8/14/2026 | 000090883426000432 |
| 2026 Q1 | 1 | $1.5B | — | new holds | 8/14/2026 | 000090883426000434 |
| 2026 Q1 | 172 | $17.5B | −17.2% | 13F-HR | 5/15/2026 | 000090883426000240 |
| 2025 Q4 | 1 | $1B | — | new holds | 8/14/2026 | 000090883426000433 |
| 2025 Q4 | 2 | $884M | — | new holds | 5/15/2026 | 000090883426000241 |
| 2025 Q4 | 151 | $21.2B | −13.2% | 13F-HR | 2/17/2026 | 000090883426000087 |
| 2025 Q3 | 144 | $24.4B | — | RESTATEMENT | 2/17/2026 | 000090883426000086 |
| 2025 Q3 | 144 | $24.4B | +5.4% | 13F-HR | 11/14/2025 | 000090883425000353 |
| 2025 Q2 | 1 | $140M | — | new holds | 2/17/2026 | 000090883426000085 |
| 2025 Q2 | 3 | $483M | — | new holds | 11/14/2025 | 000090883425000352 |
| 2025 Q2 | 141 | $23.2B | +29.2% | 13F-HR | 8/14/2025 | 000090883425000248 |
| 2025 Q1 | 1 | $274M | — | new holds | 2/17/2026 | 000090883426000084 |
| 2025 Q1 | 3 | $416M | — | new holds | 11/14/2025 | 000090883425000351 |
| 2025 Q1 | 7 | $2.2B | — | new holds | 8/14/2025 | 000090883425000247 |
| 2025 Q1 | 135 | $17.9B | −9.0% | 13F-HR | 5/15/2025 | 000090883425000177 |
| 2024 Q4 | 1 | $85M | — | new holds | 2/17/2026 | 000090883426000083 |
| 2024 Q4 | 2 | $349M | — | new holds | 11/14/2025 | 000090883425000350 |
| 2024 Q4 | 6 | $2.3B | — | new holds | 8/14/2025 | 000090883425000246 |
| 2024 Q4 | 4 | $333M | — | new holds | 5/15/2025 | 000090883425000180 |
| 2024 Q4 | 138 | $19.7B | −3.5% | 13F-HR | 2/14/2025 | 000090883425000081 |
| 2024 Q3 | 1 | $145M | — | new holds | 11/14/2025 | 000090883425000349 |
| 2024 Q3 | 6 | $1.5B | — | new holds | 8/14/2025 | 000090883425000243 |
| 2024 Q3 | 3 | $216M | — | new holds | 5/15/2025 | 000090883425000179 |
| 2024 Q3 | 2 | $544M | — | new holds | 2/14/2025 | 000090883425000080 |
| 2024 Q3 | 153 | $20.4B | −3.6% | 13F-HR | 11/14/2024 | 000090883424000307 |
| 2024 Q2 | 1 | $120M | — | new holds | 11/14/2025 | 000090883425000348 |
| 2024 Q2 | 5 | $1.2B | — | new holds | 8/14/2025 | 000090883425000245 |
| 2024 Q2 | 1 | $199M | — | new holds | 5/15/2025 | 000090883425000178 |
| 2024 Q2 | 2 | $452M | — | new holds | 2/14/2025 | 000090883425000079 |
| 2024 Q2 | 1 | $149M | — | new holds | 11/14/2024 | 000090883424000324 |
| 2024 Q2 | 157 | $21.2B | −4.2% | 13F-HR | 8/14/2024 | 000090883424000200 |
| 2024 Q1 | 1 | $93M | — | new holds | 11/14/2025 | 000090883425000347 |
| 2024 Q1 | 4 | $1.2B | — | new holds | 8/14/2025 | 000090883425000244 |
| 2024 Q1 | 2 | $159M | — | new holds | 2/14/2025 | 000090883425000078 |
| 2024 Q1 | 1 | $45M | — | new holds | 8/14/2024 | 000090883424000202 |
| 2024 Q1 | 167 | $22.1B | — | RESTATEMENT | 5/24/2024 | 000090883424000159 |
| 2024 Q1 | 167 | $22.1B | +9.8% | 13F-HR | 5/15/2024 | 000090883424000135 |
| 2023 Q4 | 1 | $65M | — | new holds | 11/14/2025 | 000090883425000346 |
| 2023 Q4 | 2 | $548M | — | new holds | 8/14/2025 | 000090883425000250 |
| 2023 Q4 | 5 | $1.1B | — | new holds | 5/15/2024 | 000090883424000141 |
| 2023 Q4 | 150 | $20.1B | +1.0% | 13F-HR | 2/14/2024 | 000090883424000070 |
| 2023 Q3 | 1 | $40M | — | new holds | 11/14/2025 | 000090883425000345 |
| 2023 Q3 | 1 | $40M | — | new holds | 5/15/2024 | 000090883424000138 |
| 2023 Q3 | 2 | $1.4B | — | new holds | 2/14/2024 | 000090883424000077 |
| 2023 Q3 | 1 | $1.9B | — | new holds | 2/12/2024 | 000090883424000049 |
| 2023 Q3 | 159 | $20B | +11.5% | 13F-HR | 11/14/2023 | 000090883423000150 |
| 2023 Q2 | 2 | $669M | — | new holds | 2/14/2024 | 000090883424000076 |
| 2023 Q2 | 5 | $1.4B | — | new holds | 11/14/2023 | 000090883423000157 |
| 2023 Q2 | 1 | $1.2B | — | new holds | 10/26/2023 | 000090883423000134 |
| 2023 Q2 | 165 | $17.9B | +1.3% | 13F-HR | 8/14/2023 | 000090883423000109 |
| 2023 Q1 | 2 | $234M | — | new holds | 2/14/2024 | 000090883424000075 |
| 2023 Q1 | 3 | $389M | — | new holds | 11/14/2023 | 000090883423000156 |
| 2023 Q1 | 1 | $15M | — | new holds | 8/14/2023 | 000090883423000110 |
| 2023 Q1 | 187 | $17.7B | +15.8% | 13F-HR | 5/15/2023 | 000117570723000127 |
| 2022 Q4 | 1 | $171M | — | new holds | 2/14/2024 | 000090883424000074 |
| 2022 Q4 | 3 | $485M | — | new holds | 11/14/2023 | 000090883423000155 |
| 2022 Q4 | 7 | $1B | — | new holds | 5/15/2023 | 000117570723000136 |
| 2022 Q4 | 232 | $15.3B | −9.3% | 13F-HR | 2/14/2023 | 000117570723000051 |
| 2022 Q3 | 1 | $125M | — | new holds | 2/14/2024 | 000090883424000073 |
| 2022 Q3 | 3 | $415M | — | new holds | 11/14/2023 | 000090883423000154 |
| 2022 Q3 | 5 | $411M | — | new holds | 5/15/2023 | 000117570723000135 |
| 2022 Q3 | 4 | $434M | — | new holds | 2/14/2023 | 000090966123000005 |
| 2022 Q3 | 298 | $16.8B | +3.5% | 13F-HR | 11/14/2022 | 000156761922019851 |
| 2022 Q2 | 1 | $115M | — | new holds | 2/14/2024 | 000090883424000081 |
| 2022 Q2 | 3 | $411M | — | new holds | 11/14/2023 | 000090883423000153 |
| 2022 Q2 | 2 | $337M | — | new holds | 5/15/2023 | 000117570723000134 |
| 2022 Q2 | 3 | $136M | — | new holds | 2/14/2023 | 000090966123000003 |
| 2022 Q2 | 9 | $1.2B | — | new holds | 11/14/2022 | 000156761922019862 |
| 2022 Q2 | 297 | $16.3B | −13.7% | 13F-HR | 8/15/2022 | 000156761922015953 |
| 2022 Q1 | 1 | $268M | — | new holds | 11/14/2023 | 000090883423000152 |
| 2022 Q1 | 1 | $314M | — | new holds | 5/15/2023 | 000117570723000133 |
| 2022 Q1 | 1 | $27M | — | new holds | 2/14/2023 | 000090966123000002 |
| 2022 Q1 | 3 | $186M | — | new holds | 11/14/2022 | 000156761922019864 |
| 2022 Q1 | 8 | $1.1B | — | new holds | 8/15/2022 | 000156761922015972 |
| 2022 Q1 | 307 | $18.8B | +0.4% | 13F-HR | 5/16/2022 | 000156761922010736 |
| 2021 Q4 | 1 | $227M | — | new holds | 5/15/2023 | 000117570723000132 |
| 2021 Q4 | 1 | $7M | — | new holds | 11/14/2022 | 000156761922019852 |
| 2021 Q4 | 1 | $115M | — | new holds | 8/15/2022 | 000156761922015968 |
| 2021 Q4 | 2 | $98M | — | new holds | 5/19/2022 | 000156761922011257 |
| 2021 Q4 | 6 | $833M | — | new holds | 5/16/2022 | 000156761922010757 |
| 2021 Q4 | 289 | $18.7B | −5.1% | 13F-HR | 2/14/2022 | 000156761922003965 |
| 2021 Q3 | 1 | $182M | — | new holds | 5/15/2023 | 000117570723000131 |
| 2021 Q3 | 1 | $105M | — | new holds | 8/15/2022 | 000156761922015964 |
| 2021 Q3 | 1 | $57M | — | new holds | 5/19/2022 | 000156761922011256 |
| 2021 Q3 | 3 | $998M | — | new holds | 5/16/2022 | 000156761922010753 |
| 2021 Q3 | 2 | $344M | — | new holds | 2/14/2022 | 000156761922003981 |
| 2021 Q3 | 293 | $19.7B | — | 13F-HR | 11/15/2021 | 000095012321015168 |
About
FARALLON CAPITAL MANAGEMENT, L.L.C.
87 processed 13Fs on this site · 2021 Q3–2026 Q2